Published On: Thu, Dec 10th, 2015

FDA Approves cooling cap to reduce Hair loss During Chemo

More than 66 percent of patients treated with the DigniCap reported losing less than half their hair.

DigniCap cooling system- breast cancer - not Jewish

 

the U.S. Food and Drug Administration Tuesday cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.

Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of breast cancer. Hair may fall out entirely, gradually, in sections, or may become thin. Hair loss due to cancer treatment is usually temporary, but minimizing or relieving these kinds of side effects are considered important to overall treatment.

How it works: It is a computer-controlled system that circulates cooled liquid to a head-worn cooling cap during chemotherapy treatment. The cooling cap is covered by a second cap made from neoprene, which holds the cooling cap in place and acts as an insulation cover to prevent loss of cooling.

The cooling action is intended to constrict blood vessels in the scalp, which, in theory, reduces the amount of chemotherapy that reaches cells in the hair roots. The cold also decreases the activity of the hair roots,  which slows down cell division and makes them less affected by chemotherapy. The combined actions are thought to reduce the effect chemotherapy has on the cells, which may reduce hair loss.

DigniCap may not work with some chemotherapy regimens. Interested patients should talk with their doctors.

The efficacy of the cooling system was studied in 122 Stage I and Stage II women with breast cancer who were undergoing chemotherapy that have been associated with hair loss.

 

DigniCap cooling system- breast cancer - not Jewish (2)

 

The data from this study may also be applied to some Stage III and IV breast cancer patients because they may have a benefit-risk profile comparable to the patients enrolled in this study. More than 66 percent of patients treated with the DigniCap reported losing less than half their hair.

Prevention of hair loss in these patients may be a significant benefit to their quality of life, and the risk of the chemotherapy drug missing an isolated grouping of the breast cancer cells in the scalp because of the cold cap is extremely rare.

The most common side effects of the cooling system include cold-induced headaches and neck and shoulder discomfort, chills, and pain associated with wearing the cooling cap for an extended period of time.

The DigniCap Cooling System is manufactured by Dignitana Inc., in Lund, Sweden.

 

Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems